Dihydrofolate Reductase Inhibitors as Anticancer Agents: Progress and Perspectives in Drug Design and Development-Reference-Cited by-同舟云学术

Dihydrofolate Reductase Inhibitors as Anticancer Agents: Progress and Perspectives in Drug Design and Development

Published:2024 Issue: Volume: Page:
ISSN:2731-4561
Container-title:Interdisciplinary Cancer Research
language:
Short-container-title:

Author:

Kong Dickson,Dolzhenko Anton V.

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/16833_2024_229

Reference190 articles.

1. Abali EE, Skacel NE, Celikkaya H, Hsieh YC (2008) Regulation of human dihydrofolate reductase activity and expression. In: Vitamins & Hormones. Academic Press, pp 267–292

2. Adjei AA (2003) Pemetrexed (Alimta®): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 3:145–156. https://doi.org/10.1586/14737140.3.2.145

3. Allegra CJ, Chabner BA, Tuazon CU, Ogata-Arakaki D, Baird B, Drake JC, Simmons JT, Lack EE, Shelhamer JH, Balis F, Walker R, Kovacs JA, Lane HC, Masur H (1987) Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 317:978–985. https://doi.org/10.1056/nejm198710153171602

4. Al-Omary FAM, Abou-zeid LA, Nagi MN, Habib E-SE, Abdel-Aziz AAM, El-Azab AS, Abdel-Hamide SG, Al-Omar MA, Al-Obaid AM, El-Subbagh HI (2010) Non-classical antifolates, Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorg Med Chem 18:2849–2863. https://doi.org/10.1016/j.bmc.2010.03.019

5. Al-Omary FAM, Hassan GS, El-Messery SM, Nagi MN, Habib E-SE, El-Subbagh HI (2013) Nonclassical antifolates, Part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones. Eur J Med Chem 63:33–45. https://doi.org/10.1016/j.ejmech.2012.12.061